Xsensio

Xsensio is a Swiss deep-tech company pioneering a Lab-on-Skin™ sensing platform designed for continuous, real-time biochemical monitoring. Their innovative technology aims to revolutionize patient monitoring by enabling the earlier detection of clinical deterioration through the tracking of inflammation and other critical biomarkers. Initial applications of their platform are focused on high-impact challenges in critical care, oncology, and post-surgical recovery, extending from ICU settings to outpatient care and home environments.

The company's core technology, the Lab-on-Skin™ sensing chip, was developed at the Nanolab of the Swiss Federal Institute of Technology (EPFL). This highly-miniaturized platform leverages semiconductor properties to unlock new possibilities in continuous health monitoring. Xsensio's vision is to become a global leader in wearable biosensors, empowering billions of people worldwide to make better daily health decisions through simple and minimally invasive data collection.

Xsensio successfully closed a $7 million (or €6 million) oversubscribed Series A financing round, led by VC firm WI Harper, with participation from Privilège Ventures, the European Innovation Council, and private investors across the United States, Europe, and Asia. [cite: 8 in previous turn, 7 in previous turn] The company has also established a long-term collaboration with Texas Instruments, a global leader in semiconductor technology, to strengthen its path to advanced, scalable semiconductor solutions. [cite: 1 in previous turn, 7 in previous turn] Xsensio has been recognized for its innovation, being listed by TIME Magazine among the 'World’s Top Healthtech Companies 2025'. [cite: 4 in previous turn, 5 in previous turn]

The Xsensio team comprises experienced scientists, engineers, and business developers. Co-founder and CEO Esmeralda Megally brings a background in investment, having managed investment opportunities at Boston-based Commons Capital in partnership with the Bill and Melinda Gates Foundation. Co-founder and CTO Prof. Adrian Ionescu leads the Nanolab at EPFL and has an extensive publication record in international journals. The Board of Directors includes Jacqueline Ruedin Rüsch, a General Partner at Privilège Ventures, and Nicola Bramwell, who has over 20 years of experience in the life sciences, biotech, and diagnostic industries. [cite: 3, 5 in previous turn, 7 in previous turn]